FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:191-193 January 12, 2006 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Iacono, A. T. PubMed Citation

During the past two decades, lung transplantation has evolved from a new investigational intervention performed in fewer than 20 patients per year at one institution to an accepted, albeit complex, therapy for a wide variety of end-stage lung diseases that is performed in more than 1700 patients annually at nearly 150 centers worldwide.¹ Early graft failures and deaths of patients were attributable to an amalgam of technical complications, opportunistic infections, and acute rejection. Refinements in surgical technique, enhanced graft preservation, and the routine use of contemporary monitoring and prophylactic and preemptive regimens for opportunistic viruses, fungi, and protozoan organisms have . . . [Full Text of this Article]

Source Information

From the Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Boston.

This article has been cited by other articles:

• Verleden, G. M., Dupont, L. J., Iacono, A. T., Johnson, B. A., Corcoran, T. E. (2006). Inhaled cyclosporine in lung transplantation.. NEJM 354: 1752-1753 [Full Text]  
• Tonks, A. (2006). What's new in the other general journals. BMJ 332: 163-164 [Full Text]